These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 21060036)
1. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. Wolf SL; Qin R; Menon SP; Rowland KM; Thomas S; Delaune R; Christian D; Pajon ER; Satele DV; Berenberg JL; Loprinzi CL; J Clin Oncol; 2010 Dec; 28(35):5182-7. PubMed ID: 21060036 [TBL] [Abstract][Full Text] [Related]
2. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131 [TBL] [Abstract][Full Text] [Related]
3. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485 [TBL] [Abstract][Full Text] [Related]
4. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949 [TBL] [Abstract][Full Text] [Related]
5. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Son HS; Lee WY; Lee WS; Yun SH; Chun HK Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420 [TBL] [Abstract][Full Text] [Related]
6. Topical henna for capecitabine induced hand-foot syndrome. Yucel I; Guzin G Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735 [TBL] [Abstract][Full Text] [Related]
7. A Randomized Single-Blinded Phase II Trial Comparing Efficacy and Quality of Life of Topical Aloe Vera Gel Plus Urea Cream Versus Urea Cream Alone for Prevention of Hand Foot Syndrome in Cancer Patients Receiving Capecitabine. Wanichtanom L; Vrakornvoravuti G; Boonsiri M; Suthepwanon A Asian Pac J Cancer Prev; 2024 Jun; 25(6):2203-2210. PubMed ID: 38918684 [TBL] [Abstract][Full Text] [Related]
8. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. Zhang RX; Wu XJ; Lu SX; Pan ZZ; Wan DS; Chen G J Cancer Res Clin Oncol; 2011 Jun; 137(6):953-7. PubMed ID: 21113620 [TBL] [Abstract][Full Text] [Related]
10. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial. Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540 [TBL] [Abstract][Full Text] [Related]
11. Capecitabine and hand-foot syndrome. Saif MW Expert Opin Drug Saf; 2011 Mar; 10(2):159-69. PubMed ID: 21174613 [TBL] [Abstract][Full Text] [Related]
12. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Lee SD; Kim HJ; Hwang SJ; Kim YJ; Nam SH; Kim BS Korean J Intern Med; 2007 Jun; 22(2):109-12. PubMed ID: 17616027 [TBL] [Abstract][Full Text] [Related]
14. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? Do JE; Kim YC Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060 [TBL] [Abstract][Full Text] [Related]
15. [Management of capecitabine-induced hand-foot syndrome by local phytotherapy]. Kern E; Schmidinger M; Locker GJ; Kopp B Wien Med Wochenschr; 2007; 157(13-14):337-42. PubMed ID: 17704983 [TBL] [Abstract][Full Text] [Related]
16. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495 [TBL] [Abstract][Full Text] [Related]
17. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291 [TBL] [Abstract][Full Text] [Related]
18. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Saif MW; Elfiky A; Diasio R Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792 [TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A Trials; 2022 May; 23(1):420. PubMed ID: 35590388 [TBL] [Abstract][Full Text] [Related]
20. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Zhang RX; Wu XJ; Wan DS; Lu ZH; Kong LH; Pan ZZ; Chen G Ann Oncol; 2012 May; 23(5):1348-1353. PubMed ID: 21940785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]